Dova Pharmaceuticals, Inc.

26 articles with Dova Pharmaceuticals, Inc.

• China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

  4/30/2020

  First Approval for DOPTELET in China and First-Ever Treatment for this Indication in China

• Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia

  1/13/2020

  Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB, has been granted Orphan Drug Designation1 by the US Food and Drug Administration for avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia.

• FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia

  12/21/2019

  Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB has been granted Orphan Drug Designation[1] by the US Food and Drug Administration for avatrombopag for the potential treament of Chemotherapy-Induced Thrombocytopenia.

• Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

  12/9/2019

  Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag for the treatment of immune thrombocytopenia, at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.

• Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

  12/9/2019

  Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented data on the cost effectiveness of Doptelet® for the treatment of thrombocytopenia in patients with chronic liver diseases who are scheduled to undergo a procedure at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.

• Results from a Survey With Patients With Immune Thrombocytopenia (ITP) Demonstrates Disease Burden and Impact for Patients With ITP

  12/8/2019

  Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB, presented results from an online survey highlighting disease burden and impact for patients with immune thrombocytopenia, at the 61st Annual Meeting of the American Society of Hematology taking place in Orlando, 7-10 December.

• Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology

  9/30/2019

  Swedish Orphan Biovitrum AB announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. by means of a tender offer.

• 

  Sweden’s Sobi to Acquire Dova Pharmaceuticals in $915 Million Deal

  9/30/2019

  Shares of Dova Pharmaceuticals are up more than 38% in premarket trading after Sobi announced its intentions to acquire the company for $915 million.
• 

  FDA Action Alert: Regeneron, Sanofi, Celgene

  6/24/2019

  July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.

• Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

  9/27/2018

  Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure

• 

  FDA Approves Shionogi’s Mulpleta

  8/1/2018

  Shionogi, based in Osaka, Japan and Florham Park, New Jersey, announced that the U.S. Food and Drug Administration (FDA) approved Mulpleta (lusutrombopag) for thrombocytopenia in adults with chronic liver disease who were about to have a medical procedure performed.
• 

  Approved! FDA gives Dova Pharma’s Doptelet a Thumbs Up

  5/22/2018

  Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
• 

  Three Companies with FDA Decisions in the Next Week

  5/15/2018

  There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.

• Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018

  2/13/2018

  To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.

• Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as CFO

  1/30/2018

  Mark will officially commence in his role as Chief Financial Officer of Dova on January 31st, 2018.

• Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag NDA With Priority Review

  11/28/2017

  The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is May 21, 2018.

• Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results

  11/10/2017

  Dova reported a net loss of $9.7 million for the third quarter of 2017, compared to a net loss of $7.2 million for the same period in 2016.

• Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017

  11/3/2017

  A question-and-answer session will follow Dova's remarks.

• Dova Pharma To Present Phase III Avatrombopag Data At The 2017 Liver Meeting Of The American Association For The Study Of Liver Diseases (AASLD)

  10/11/2017

• Dova Pharma Announces New Drug Application Submission To FDA For Avatrombopag, A Second Generation Thrombopoietin Receptor Agonist

  9/22/2017